ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc (APLS)

38.725
1.34
( 3.57% )
Updated: 15:05:46

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
38.725
Bid
38.70
Ask
38.75
Volume
814,511
37.22 Day's Range 39.74
19.8301 52 Week Range 73.80
Market Cap
Previous Close
37.39
Open
37.22
Last Trade
100
@
38.725
Last Trade Time
15:05:45
Financial Volume
$ 31,562,994
VWAP
38.7509
Average Volume (3m)
1,365,625
Shares Outstanding
121,365,555
Dividend Yield
-
PE Ratio
-8.97
Earnings Per Share (EPS)
-4.33
Revenue
396.59M
Net Profit
-525.63M

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the... Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
Apellis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker APLS. The last closing price for Apellis Pharmaceuticals was $37.39. Over the last year, Apellis Pharmaceuticals shares have traded in a share price range of $ 19.8301 to $ 73.80.

Apellis Pharmaceuticals currently has 121,365,555 shares outstanding. The market capitalization of Apellis Pharmaceuticals is $4.54 billion. Apellis Pharmaceuticals has a price to earnings ratio (PE ratio) of -8.97.

Apellis Pharmaceuticals (APLS) Options Flow Summary

Overall Flow

Bearish

Net Premium

-26k

Calls / Puts

0.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

APLS Latest News

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, July 18, 2024 NEW YORK, July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second...

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study WALTHAM, Mass., July 09, 2024...

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10...

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global...

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were clearedHighlighted as...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.055-2.6520864756239.7839.8436.3155117037.36440547CS
4-1.645-4.0748080257640.3742.4734.69136953837.83310852CS
12-7.895-16.934791934846.6249.0634.69136562540.46812615CS
26-28.875-42.714497041467.671.934.69139607950.63854992CS
526.47520.077519379832.2573.819.8301232727044.8983333CS
156-29.445-43.193486871168.1794.7519.8301178398250.48424843CS
2609.77533.765112262528.9594.7516.85140624647.50497803CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SLRXSalarius Pharmaceuticals Inc
$ 3.5399
(65.42%)
29.95M
POAIPredictive Oncology Inc
$ 1.69
(57.94%)
155.74M
PBMPsyence Biomedical Ltd
$ 0.5866
(49.87%)
79.71M
CMAXCareMax Inc
$ 5.7087
(47.13%)
23.17M
SERVServe Robotics Inc
$ 11.924
(39.30%)
28.24M
TWOU2U Inc
$ 1.5005
(-63.58%)
5M
XPONExpion360 Inc
$ 0.55
(-47.12%)
988.37k
EZFLEzFill Holdings Inc
$ 3.809
(-38.81%)
172.33k
KDLYKindly MD Inc
$ 2.104
(-34.66%)
799.83k
MXLMaxLinear Inc
$ 14.9534
(-32.91%)
4.94M
NVDANVIDIA Corporation
$ 114.01
(-0.21%)
386.06M
SQQQProShares UltraPro Short QQQ
$ 9.15
(0.99%)
220.47M
SLNASelina Hospitality PLC
$ 0.0394
(-13.79%)
175.01M
POAIPredictive Oncology Inc
$ 1.69
(57.94%)
155.74M
TSLATesla Inc
$ 223.56
(3.50%)
84.37M

APLS Discussion

View Posts
Dennisb68 Dennisb68 8 months ago
$60.00, that didn’t take long!
👍️0
Dennisb68 Dennisb68 8 months ago
I like the way this traded today, $60 in the near future on news?
👍️0
Dennisb68 Dennisb68 10 months ago
Holding up well..
👍️0
doholic11 doholic11 12 months ago
Finally! Back up 14% today.
👍️0
pitacorp pitacorp 1 year ago
Shorts got another 12 to 13% since you're warning, let's hope your warning sticks today...
👍️0
Stockexpertpro Stockexpertpro 1 year ago
APLS Time to Cover Shorts just like i told the shorts last week on ARGX to Buy to Cover
👍️0
IPO$ IPO$ 1 year ago
Closed out of puts at 99% profit on this one. Only three week hold.
👍️0
IPO$ IPO$ 1 year ago
Why is stock up so much???
👍️0
IPO$ IPO$ 1 year ago
Stock up big today.
👍️0
IPO$ IPO$ 1 year ago
FDA announcement soon.
👍️0
IPO$ IPO$ 1 year ago
Puts are very pricey and out of the money. Sell for cash to acct.
👍️0
IPO$ IPO$ 1 year ago
Why up today? As stock goes up, puts go up too. Strange.
👍️0
IPO$ IPO$ 1 year ago
Will we get FDA approval???
👍️0
IPO$ IPO$ 1 year ago
Heavy premium in the puts and calls.
👍️0
IPO$ IPO$ 1 year ago
2/8/23 regulatory decision due on Empavali.
👍️0
conix conix 2 years ago
Huge Market

👍️0
conix conix 2 years ago
Drug trial for dry AMD slows progression of disease

Posted: Tuesday 29 March 2022

A drug being trialled for dry age-related macular degeneration (AMD) can significantly reduce the progression of the disease, according to new studies.

Phase three trials have shown that injections of a drug called pegcetacoplan resulted in a significant reduction in the rate at which the cells of the macular degenerate.

The studies by Apellis Pharmaceuticals built on previous research which showed that dry AMD is linked to the complement system and a hyperactive immune response that damages the eyes. Pegcetacoplan is a complement system inhibitor, meaning it aims to prevent this response from happening and harming healthy cells and tissue.

The studies involved two phase three clinical trials (DERBY and OAKS) involving more than 1,250 patients with late stage dry AMD, often referred to as geographic atrophy (GA). As part of the trials some patients received injections monthly, while others received them every other month.

In the combined results of the two trials, patients who received the drug monthly showed up to a 21% reduction in progression of the disease after 18 months, while those who were injected every other month had a 17% reduction.

Jeffrey S. Heier, principal investigator of the DERBY study from Ophthalmic Consultants of Boston, said: “It is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time. These 18-month results provide further evidence that pegcetacoplan meaningfully slows disease progression and has the potential to preserve vision longer.”

He added: “In my practice, I have seen how devastating it can be for people living with GA to lose more of their vision year after year. There is an urgent unmet need in GA, and these results reinforce the potential of pegcetacoplan to become the first-ever treatment for patients with this debilitating disease.”

The study also found that pegcetacoplan was generally safe and well tolerated by those on the trial.

Results of the studies are to be submitted to the US Food and Drug Administration (FDA) for review by the end of June 2022, with the hope that the drug will be licenced for use in the USA.
👍️0
PickleNick PickleNick 3 years ago
Going back to 60 this week
👍️0
wantprofits wantprofits 5 years ago
looks like insider dumping may be happening again.. damnit
👍️0
Pedro2004 Pedro2004 5 years ago
Be careful with this company.
There was a great PR.
An insider dump.
Then a 7 million share under-market private placement.
Then another insider dump the next day.

Scam company.
👍️0
ClayTrader ClayTrader 5 years ago
* * $APLS Video Chart 01-07-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ComptonBrosInc ComptonBrosInc 5 years ago
First! Holding $40 2/21 call... waiting on trial results!
👍️0

Your Recent History

Delayed Upgrade Clock